TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04211727

Intervention type: DIAGNOSTIC_TEST
Intervention: Capillary finger prick blood sample
Description: Patients will have a blood finger prick sample

Intervention type: DIAGNOSTIC_TEST
Intervention: Capillary finger prick blood sample
Description: Patients will have a blood finger prick sample
Study: NCT01912027

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Latarjet technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic Latarjet techniques
Study: NCT04959318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Professional nutrition counseling
Description: Published multi-cohort genome-wide association studies provided genes and genetic variants that are credibly associated with aspects of metabolic syndrome (MetS), CVD, overweight/obesity, and vitamin D metabolism. Registered dietitian (RD) counseling will review potentially harmful and protective variants for risk of MetS with subjects and make evidence-based recommendations to improve diet quality and achieve weight loss goals. Each of the 6 weekly sessions covered a specific component of MetS. Counseling will take place once a week either in-person or via phone/virtual platform based on preference and availability of the subject. Counselors will review digital app data entries for food intake prior to this interaction for the first 2 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No professional nutrition counseling
Description: Participants receive pamphlets with evidence-based general health, healthy nutrition, exercise and sleep content. They receive information on genetic variants related to MetS at end of study period.
Study: NCT02532725

Intervention type: PROCEDURE
Intervention: Cardiopulmonary Exercise Stress Test
Description: Test preceded by warm-up treadmill walking 5 min at 4.8 km/h, 5% grade with a 1 min sitting rest period. Test, then, begins at 4.8 km/h, 2.5% grade with incremental grade increases every 2 min until exhaustion. Ambient environment is maintained at neutral, with effective temperature of 19-21° C. Heart, lungs, temperature, and sweating is monitored during testing.

Intervention type: PROCEDURE
Intervention: Cardiopulmonary Exercise Stress Test
Description: Test preceded by warm-up treadmill walking 5 min at 4.8 km/h, 5% grade with a 1 min sitting rest period. Test, then, begins at 4.8 km/h, 2.5% grade with incremental grade increases every 2 min until exhaustion. Ambient environment is maintained at neutral, with effective temperature of 19-21° C. Heart, lungs, temperature, and sweating is monitored during testing.

Intervention type: PROCEDURE
Intervention: Climatic-Controlled Cardiopulmonary Exercise Stress Test
Description: Test includes 30 min walking bouts on the treadmill, with two 5 min sitting rest periods between bouts (Rest I and Rest II) and 15 min sitting recovery period (Rest III), in effective temperatures of 21.1 (baseline), 26.7, 29.4, 32.2, and 35.0° C. Heart, lungs, temperature, and sweating is monitored during testing.

Intervention type: PROCEDURE
Intervention: Climatic-Controlled Cardiopulmonary Exercise Stress Test
Description: Test includes 30 min walking bouts on the treadmill, with two 5 min sitting rest periods between bouts (Rest I and Rest II) and 15 min sitting recovery period (Rest III), in effective temperatures of 21.1 (baseline), 26.7, 29.4, 32.2, and 35.0° C. Heart, lungs, temperature, and sweating is monitored during testing.

Intervention type: PROCEDURE
Intervention: Body Composition Evaluation
Description: Multiple methods are used to accurately estimate percentage of body mass (weight) composed of fat, muscle, bone, and other connective tissues. Four different methods, including caliper and hydrostatic (underwater weighing) are used in this study to ensure an accurate estimation.

Intervention type: PROCEDURE
Intervention: Body Composition Evaluation
Description: Multiple methods are used to accurately estimate percentage of body mass (weight) composed of fat, muscle, bone, and other connective tissues. Four different methods, including caliper and hydrostatic (underwater weighing) are used in this study to ensure an accurate estimation.

Intervention type: PROCEDURE
Intervention: Pre-Exercise Risk Assessment
Description: Includes non-invasive measurements of body functioning, a physical examination by a physician, and blood and urine testing to select subjects who can exercise with relative safety.

Intervention type: PROCEDURE
Intervention: Pre-Exercise Risk Assessment
Description: Includes non-invasive measurements of body functioning, a physical examination by a physician, and blood and urine testing to select subjects who can exercise with relative safety.
Study: NCT03074123

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: low-dose cosyntropin stimulation test
Description: Each subject recruited in the study will undergo low dose cosyntropin stimulation test via intravenous short 2.5 cm plastic tube. 1 μg/ml ACTH aliquot stock solution will be pushed through, followed by 5 ml physiologic saline (0.9%). For each subject, serum and salivary cortisol will be measured just before cosyntropin administration and 30 minutes later.
Study: NCT03249337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ripasudil hydrochloride hydrate 0.4% ophthalmic solution
Description: the ophthalmic solution will be administered three or six per times per day in the eye designated as the Study Eye upon study enrollment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ripasudil hydrochloride hydrate 0.4% ophthalmic solution
Description: the ophthalmic solution will be administered three or six per times per day in the eye designated as the Study Eye upon study enrollment
Study: NCT03260985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feedback Report
Description: A report of the data from the comprehensive neuroscience assessment is provided to the patient's care team.
Study: NCT00902850

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SofLens Daily Disposable
Description: Lenses to be worn for 8-16 hours

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed 1 Day Contact Lens
Description: Lenses to be worn for 8-16 hours
Study: NCT01111734

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: All eligible study subjects will be treated with 600mg of N-Acetylcysteine orally twice a day for 2 weeks, then the dose will be increased to 1200mg twice a day for two weeks, and to 1800mg twice a day for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fMRI
Description: All eligible subjects and controls will undergo an emotional face-viewing task in our fMRI paradigm in order to focus in on the circuitry related to affect processing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fMRI
Description: All eligible subjects and controls will undergo an emotional face-viewing task in our fMRI paradigm in order to focus in on the circuitry related to affect processing.
Study: NCT01019122

Intervention type: RADIATION
Intervention: Dexa Scan
Description: Dexa scan of left and right distal femur, then lumbar spine, and whole body when possible
Study: NCT00584532

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 Placebo Capsules taken orally every day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GCP - Genistein Combined Polysaccharide
Description: Ten 500 mg capsules given orally per day. Total of 5 grams per day per patient.
Study: NCT03200483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Protocol
Description: In this period the volunteers were at rest, in the supine position for 15 minutes, followed by 30 minutes of aerobic exercise on a treadmill (five minutes at a speed of 6.0 km / h followed by 25 minutes with 60% of Vmax + 1% grade) and then a recovery period lasting 60 minutes (three minutes standing on the treadmill followed by 57 minutes in the supine position). The volunteers were instructed to remain awake during all the protocol and this was verified and monitored by one of the researchers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical Music Protocol
Description: Volunteers accomplished the same activities of the control protocol, but with exposure to classical music during exercise and recovery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rock Music Protocol
Description: Volunteers accomplished the same activities of the control protocol, but with exposure to rocky musical style during exercise and recovery.
Study: NCT02371785

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CorPath 200 System
Description: Remote delivery of guide wires and balloon catheters for use in percutaneous vascular interventions (PVI).
Study: NCT01181804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir
Description: Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir
Description: Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir
Description: Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir
Description: Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
Study: NCT04307069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: The drug wil be adminisrate for augmentation of labor at admission.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: The drug wil be adminisrate for augmentation of labor at admission.
Study: NCT03168165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education training
Description: PNE training will consist of 6 weeks online training followed by one day training session.
Study: NCT03953248

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Carnitine
Study: NCT04061824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olostar Tab (olmesartan/rosuvastatin FDC(fixed dose combination))
Description: In intervention group, patients had a pill of fixed-dose combination of Olmesartan medoxomil and Rosuvastatin, rather taking separated two pills.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Two separated drugs(ARB(Angiotensin Ⅱ receptor blocker) and statin)
Description: In control group, patients had two separated pills for hypertension and dyslipidemia. One of ARBs(Valsartan, Olmesartan, Candesartan, Telmisartan, Fimasartan, Losartan and Irbesartan) and one of statins(Rosuvastatin, Atorvastatin, Pitavastatin, Simvastatin, Pravastatin, Fluvastatin and Atorvastatin/Ezetimibe).
Study: NCT01849393

Intervention type: OTHER
Intervention: Questionnaire
Description: Participants who consent to participate in this study will complete a short questionnaire. The survey will be completely anonymous (not matched with the participant's name). Estimated time to complete the survey is 10-20 minutes.
Study: NCT05659043

Intervention type: OTHER
Intervention: overnight fasting
Description: All blood samples were taken on the day of cardiac catheterization after overnight fasting.

Intervention type: OTHER
Intervention: overnight fasting
Description: All blood samples were taken on the day of cardiac catheterization after overnight fasting.
Study: NCT03075280

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 400ml high carbohydrate liquid diet before ERCP
Description: 400ml high carbohydrate liquid diet uptake 2 hours before ERCP
Study: NCT04416334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine plus symptomatic treatment (paracetamol)
Description: Colchicine plus symptomatic treatment (paracetamol).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations)
Description: Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations).
Study: NCT02819986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Goal Attainment Program
Description: Behavioural intervention that consists of 10 one hour weekly therapy sessions that focus on goal setting, challenging thoughts about return to work, problem solving, behavioural activation, and resuming occupational roles.
Study: NCT03525600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-2
Description: Complement (C3) Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-2
Description: Complement (C3) Inhibitor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: Subjects will receive a Sham procedure every month

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: Subjects will receive a Sham procedure every other month
Study: NCT04087031

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control arm
Description: Each session will include 50 minutes of traditional physical rehabilitation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality games
Description: Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic Tymo system (Tyromotion, Austria), a wireless static and dynamic platform, for evaluating and rehabilitating posture.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: robotic treadmill
Description: Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic Walker View (TecnoBody, Italy) a treadmill equipped with a sensorized belt with eight load cells and a 3D camera
Study: NCT03884387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Decision Aid
Description: The Patient Decision aid used in this project is a tool designed to facilitate shared decision making in patients with lumbar herniated disk. It is intended to complement counseling with health professionals and help patients become involved in decision making by making explicit the decision that needs to be made, providing information about the advantages and disadvantages of having or not having surgery, knowledge of treatment outcomes, and by clarifying personal values.
Study: NCT02940535

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human chorionic gonadotropin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human chorionic gonadotropin
Study: NCT00778076

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Description: 3 consecutive injections, each one week apart, of 20mg/2ml Hyaluronic acid.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saline injection)
Description: 3 consecutive injections, each one week apart, of 20mg/2ml of Placebo.
Study: NCT01471769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain management video
Description: 6-minute video

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Falls Prevention Video
Description: 6-minute video
Study: NCT01740921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Administered once daily
Study: NCT02362061

Intervention type: RADIATION
Intervention: 3D ultrasound
Description: ultrasound to measure the thickness of the junctional zone at day 21 of the cycle

Intervention type: RADIATION
Intervention: 3D ultrasound
Description: ultrasound to measure the thickness of the junctional zone at day 21 of the cycle
Study: NCT02590367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: FOLFOX regimens are combination therapy of oxaliplatin (85 mg/m\^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m\^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (different dose like FOLFOX4/FOLFOX6) via ambulatory pump administered for a period of 46 to 48 hours.~XELOX is a combination therapy of Oxaliplatin 130mg/ m\^2 d1 Intravenous infusion, every 3 weeks. and Capecitabine 1000mg/m\^2 bid, days 1-14, every 3 weeks.
Study: NCT01740921

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: diet
Description: reduction of caloric intake to promote weight loss

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: 300mg of Aspirin per day
Study: NCT01018017

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRT2104
Description: SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg SRT2104.
Study: NCT01014936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2156119J

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2156119J

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2156119J
Study: NCT01185951

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polidocanol
Description: Power-Doppler-guided extratendinous sclerosing therapy using Polidocanol 0.5% up to 2ml every 6-8 weeks
Study: NCT00228189

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CEA-loaded dendritic cell vaccine
Description: Carcinoembryonic antigen (either peptide or mRNA) loaded dendritic cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CEA-loaded dendritic cell vaccine
Description: Carcinoembryonic antigen (either peptide or mRNA) loaded dendritic cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CEA-loaded dendritic cell vaccine
Description: Carcinoembryonic antigen (either peptide or mRNA) loaded dendritic cells.
Study: NCT01232192

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: antenatal model
Description: Antenatal model is consisted of integrated efforts to lower preterm delivery rate through early detection and bacterial vaginal infection treatment:~* Midwife training~* Pregnant women campaigning~* Early detection with self pH detection~* Treatment of bacterial vaginosis

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: antenatal model
Description: Antenatal model is consisted of integrated efforts to lower preterm delivery rate through early detection and bacterial vaginal infection treatment:~* Midwife training~* Pregnant women campaigning~* Early detection with self pH detection~* Treatment of bacterial vaginosis
Study: NCT03780413

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PR-ESSENCE treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control (TAU)
Study: NCT02154334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Participants will self-administer one Intranasal spray of 14 mg esketamine solution in each nostril on Day 1 at time 0 and 5 minutes (total esketamine dose will be 56 mg) in Period 1 and Period 2.
Study: NCT01185951

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polidocanol
Description: Power-Doppler-guided extratendinous sclerosing therapy using Polidocanol 0.5% up to 2ml every 6-8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polidocanol
Description: Power-Doppler-guided extratendinous sclerosing therapy using Polidocanol 0.5% up to 2ml every 6-8 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Focused extracorporeal shock wave therapy
Description: Focused extracorporeal shock wave therapy using a STORZ Duolith machine 2000 Impulses 0.25mJ/mm2 every 6-8 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Focused extracorporeal shock wave therapy
Description: Focused extracorporeal shock wave therapy using a STORZ Duolith machine 2000 Impulses 0.25mJ/mm2 every 6-8 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Focused extracorporeal shock wave therapy
Description: Focused extracorporeal shock wave therapy using a STORZ Duolith machine 2000 Impulses 0.25mJ/mm2 every 6-8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical NO
Description: Topical nitroglycerine (Nitrolingualspray(R)) 2x2 hubs per day over 6 months daily on the painful tendon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical NO
Description: Topical nitroglycerine (Nitrolingualspray(R)) 2x2 hubs per day over 6 months daily on the painful tendon
Study: NCT02590367

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FOLFOX regimen
Description: FOLFOX regimens are combination therapy of oxaliplatin (85 mg/m\^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m\^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (different dose like FOLFOX4/FOLFOX6) via ambulatory pump administered for a period of 46 to 48 hours.~XELOX is a combination therapy of Oxaliplatin 130mg/ m\^2 d1 Intravenous infusion, every 3 weeks. and Capecitabine 1000mg/m\^2 bid, days 1-14, every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HD6610 Granule
Description: the HD6610 Granule will be given 2 times a day.
Study: NCT01185951

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical NO
Description: Topical nitroglycerine (Nitrolingualspray(R)) 2x2 hubs per day over 6 months daily on the painful tendon

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Painful eccentric training in Achilles tendinopathy
Description: Painful eccentric training for Achilles tendinopathy on a stair single-stance with 6x15 repetitions per leg and day over at least 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Painful eccentric training for patella tendinopathy on 25° decline board
Description: Painful eccentric training for patella tendinopathy on a 25° decline board single-stance with 6x15 repetitions per leg and day over at least 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Painful eccentric training for elbow tendinopathy using Thera-Band Flex-Bar
Description: Painful eccentric training for elbow tendinopathy using a green coloured Thera-Band Flex-Bar with painful supination and pronation with 6x15 repetitions per day over at least 12 weeks
Study: NCT00952328

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutramigen infant formula
Description: Investigators will advise mothers to supplement with 10 cc of elemental formula immediately following each breastfeeding and to discontinue formula once mature milk production begins.
Study: NCT01918891

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Practitioner Only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Practitioner Only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Practitioner + Health Coach
Study: NCT03522935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elafin
Description: Elafin subcutaneous.